Johnson & Johnson (XKAZ:JNJ_KZ) LT-Debt-to-Total-Asset : 0.15 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Johnson & Johnson LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Johnson & Johnson's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.15.

Johnson & Johnson's long-term debt to total assets ratio increased from Dec. 2022 (0.14) to Dec. 2023 (0.15). It may suggest that Johnson & Johnson is progressively becoming more dependent on debt to grow their business.

Johnson & Johnson LT-Debt-to-Total-Asset Historical Data

The historical data trend for Johnson & Johnson's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson LT-Debt-to-Total-Asset Chart

Johnson & Johnson Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.17

0.19

0.17

0.14

0.15

Johnson & Johnson Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.18	0.18	0.16	0.15	-

Johnson & Johnson LT-Debt-to-Total-Asset Calculation

Johnson & Johnson's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	25881	/	167558
	=	0.15

Johnson & Johnson's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	25881	/	167558
	=	0.15

Johnson & Johnson (XKAZ:JNJ_KZ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Johnson & Johnson LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Johnson & Johnson (XKAZ:JNJ_KZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (XKAZ:JNJ_KZ) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

JNJ:USA JNJ:Peru JNJ:Mexico 1JNJ:Italy JNJd:UK 0R34:UK JNJ:Germany JNJ:Canada JNJB34:Brazil JNJ:Austria JNJ:Argentina

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

https://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson (XKAZ:JNJ_KZ) Headlines

No Headlines